In light of teptinib's recent FDA-approval for exon-14 skipping MET altered metastatic NSLCC, we compare tepotinib to its predecessor in this space - capmatinib.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
